Apple stock is up about 65% in 2019 and 125% over the past five years. It's trading at about $260 a share and continues to make all-time highs.
And yet now is the time to buy Apple stock.
It seems counterintuitive. When a stock has made the kind of gains that Apple Inc. (NASDAQ: AAPL) has, conventional wisdom says if you own it you cash out. And if you don't own it, don't buy at the top.
But Apple has never been a stock that conforms to conventional wisdom. It has "peaked" numerous times.
For instance, after the AAPL stock price hit a split-adjusted $100 a share in September 2012, many pundits soured on the company. The next year, the stock fell more than 40%, and Wall Street viewed it as "dead money."
By late 2014, Apple was back over $100 and on its way to new highs. And it's more than doubled since then.
Right now sentiment on the company is high and analysts are jacking up their Apple stock price targets. The top target is set at $300.
But as usual, Wall Street is a bit behind. Even a target of $300 is well short of where Apple shares are headed within the next two years.
"Apple is making a fundamental pivot into services and, specifically, into the single most lucrative market in the world... healthcare," said Money Morning Chief Investment Strategist Keith Fitz-Gerald. "The U.S. medical market alone for Apple-powered medical devices may be three times the entire global iPhone market. That pencils out to around $300 billion, in case you're wondering, all of which is a far higher margin."
Fitz-Gerald currently has an aggressive AAPL stock price target of $400 by mid-2021. That represents a 54% gain from the current price.
That's a pretty good reason to buy Apple stock.
And it's all here in the numbers...
Earlier this year, Morgan Stanley (NYSE: MS) did a deep dive on Apple's healthcare opportunity. And the results were staggering.
The investment bank concluded that healthcare could add anywhere from $15 billion to $313 billion annually to Apple's top line. The report pegged the midpoint at $90 billion of additional revenue by 2027.
118% on SEDG since March 22 79% on TTGT since April 12 50% on MKTX since March 26 48% on CHDN since March 22 46% on NVDA since May 28 42% on TGT since March 7 41% on ALGN since Aug. 30 40% on CMPR since June 13 34% on AMAT since April 9 30% on NB since June 13
Revenue for Apple's 2019 fiscal year (which ended Sept. 30) was $260.17 billion. So if the Morgan Stanley report is right, that represents a revenue increase of nearly 35%.
If you convert that to earnings per share, you end up with roughly an additional $4.44, which would put Apple's 2027 EPS at about $16.33. Given a price/earnings (P/E) ratio of 22 (AAPL's current P/E), you end up with a stock price of about $360 per share.
But Morgan Stanley's midline of $90 billion of additional revenue isn't in the middle of its range. The mathematical midpoint is actually $164 billion of additional revenue. If you round that down to $150 billion, you end up with an additional $7.33 in earnings.
That would put Apple's 2027 EPS at $19.22 and its share price at $422 - comfortably over our target price. The price can even get there by 2021 if Wall Street wakes up to what's happening.
The approximate revenue required just to get AAPL to $400 is $120.68 billion. Given the range in the Morgan Stanley report, that's not particularly outlandish.
I admit this all sounds a bit abstract. So let's get more concrete...
We've already seen some of the ways Apple plans to profit from healthcare, and it has more in the pipeline:
And don't underestimate Apple's advantage in having decades of experience building ecosystems.
Because Apple makes the hardware and software in addition to running the services it offers, all the pieces work together seamlessly. The one-vendor approach avoids the kinds of glitches that plague systems cobbled together from products by multiple vendors. Plus, the tight integration helps Apple keep user data secure.
All that translates very nicely to healthcare. Medical systems need to work. And patient data must be protected by law.
To be sure, Apple will have competition from other Big Tech companies. Microsoft Corp. (NASDAQ: MSFT), Amazon.com Inc. (NASDAQ: AMZN), and Alphabet Inc. (NASDAQ: GOOGL) are all known to have healthcare projects in the works.
But Apple's skills at vertical integration and emphasis on privacy will give it an edge.
Still, things could go wrong. But healthcare won't be alone in adding revenue to Apple's top line...
[mmpazkzone name="in-story" network="9794" site="307044" id="137008" type="4"]
A boost from healthcare would drive Apple's hardware sales - particularly the Watch and the iPhone - much higher than current Wall Street estimates.
But even without it, Apple will continue to see at least stable hardware sales. And that's all it will need to realize gains from another major profit center.
Here's how it will work.
Even now, Apple's hardware sales continue to expand the installed base of Apple users. In Apple's most recent quarter, the company said half the customers who bought a Mac were new to the platform. One-quarter of those who bought an iPad were new to the iPad.
The installed base matters because all those users - approximately 1 billion people own at least one Apple device - are also signing up for Apple's services. And that's where most of its revenue growth is coming from now.
Apple services include Apple Music, the App Store, the Apple-branded credit card, iCloud, and the just-launched Apple TV Plus streaming service.
Whatever happens with healthcare, Apple's services are expected to grow rapidly over the next few years. Morgan Stanley estimates revenue from Apple services will more than double from $46.3 billion in FY 2019 to about $100 billion in FY 2025.
Because services have much higher margins, that increased revenue will disproportionately fatten Apple's bottom line. RBC Capital Markets has estimated services will account for more than half of Apple's profits by then.
That figures to be about $18.9 billion in additional net income, or $4.20 per share. Adding that to Apple's current EPS puts you at $16.09. With a P/E of 22, you get an AAPL share price of $354. And remember, that excludes the gains from Apple's healthcare initiatives.
So if its healthcare business proves a big success, Apple goes to $400. But even if it's a modest success, the power of Apple's services business will pick up the slack - and Apple goes to $400.
Consider this: If you take Morgan Stanley's midline estimate of $90 billion of additional revenue and combine it with the $100 billion estimate for services revenue, you get a 2026 to 2027 EPS of $20.53. That would send Apple to $450 a share - a 73% gain from the current price.
Anyone can learn how to trade options, but not everyone has access to an arsenal of what can be unique and highly lucrative trading secrets.
Well, you can - and for just $1.
You see, America's No. 1 Pattern Trader is on a mission to help you collect the most money possible every single week.
With his seven-day video training series, you'll get an all-access pass to dozens of options trading secrets and strategies to use in the markets.
You'll be trading your way to thousands of dollars in extra income in no time...
Click here to get started.
Follow me on Twitter @DavidGZeiler and Money Morning on Twitter and Facebook.